Articles related to CLINICAL TRIALS

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

The recent phase 3 trial has demonstrated the potential of amivantamab as a first-line treatment option for patients with advanced NSCLC with EGFR exon 20 insertions. The combination of amivantamab and chemotherapy significantly improved progression-free survival compared to chemotherapy alone.

The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.

The recent study from CTAD 2023 has demonstrated the potential of p-tau217 as a promising biomarker for preclinical Alzheimer’s disease. This finding could significantly enhance our ability to detect Alzheimer’s at its earliest stages and initiate timely interventions.

The study suggests that approximately one heated yoga session per week was associated with significantly greater reduction in depression symptoms than a waitlist control. This finding indicates that heated yoga could be a viable non-medication-based treatment option for patients with moderate-to-severe depression.

The recent findings on valbenazine’s fast onset of action in treating chorea associated with HD could be a game-changer for the 30,000 Americans living with this disease.